Cargando…

Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis

BACKGROUND: Endocrine therapy is the cornerstone treatment for patients with hormone receptor-positive advanced breast cancer. We aimed to assess the effectiveness of various first-line endocrine monotherapies or combinations to determine the optimal sequence in a network meta-analysis. MATERIALS AN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Tingting, Feng, Fubin, Zhao, Wenge, Tian, Jinhui, Yao, Yan, Zhou, Chao, Dong, Shengjie, Wang, Congcong, Zang, Chuanxin, Lv, Qingliang, Sun, Changgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951224/ https://www.ncbi.nlm.nih.gov/pubmed/29780257 http://dx.doi.org/10.2147/OTT.S165681

Ejemplares similares

Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis
por: Zhang, Tingting, et al.
Publicado: (2018)

Clinicopathological characteristics and prognostic value of the cancer stem cell marker ALDH1 in ovarian cancer: a meta-analysis
por: Zhao, Wenge, et al.
Publicado: (2018)

Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults: a network meta-analysis
por: Zhang, Tingting, et al.
Publicado: (2018)

Efficacy and safety of targeted therapy for metastatic HER2-positive breast cancer in the first-line treatment: a Bayesian network meta-analysis
por: Feng, Fubin, et al.
Publicado: (2019)

Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis [Corrigendum]
Publicado: (2018)

Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis
por: Zhang, Jingwen, et al.
Publicado: (2017)

Pseudoprogression after advanced first-line endocrine therapy in metastatic breast cancer with bone metastasis: A case report
por: Tian, Aijuan, et al.
Publicado: (2023)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
por: Ng, Kenrick, et al.
Publicado: (2020)

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
por: López González, Ana, et al.
Publicado: (2022)

Integrated analysis of co‐expression and ceRNA network identifies five lncRNAs as prognostic markers for breast cancer
por: Yao, Yan, et al.
Publicado: (2019)

Hormone Production in Endocrine Tumours
por: Abelson, Denis
Publicado: (1958)

Impact of Chemical Endocrine Disruptors and Hormone Modulators on the Endocrine System
por: Guarnotta, Valentina, et al.
Publicado: (2022)

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
por: Wong, Z-W, et al.
Publicado: (2004)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment
por: Aragon-Ching, Jeanny B
Publicado: (2022)

Markers of endocrine sensitivity
por: Hayes, Daniel F
Publicado: (2008)

Hormonal treatments for endometriosis: The endocrine background
por: Vannuccini, Silvia, et al.
Publicado: (2021)

Aging under endocrine hormone regulation
por: Xing, Yutong, et al.
Publicado: (2023)

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.
por: Crighton, I. L., et al.
Publicado: (1989)

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
por: Yuan, Yang, et al.
Publicado: (2023)

Gene signatures of 6-methyladenine regulators in women with lung adenocarcinoma and development of a risk scoring system: a retrospective study using the cancer genome atlas database
por: Gao, Chundi, et al.
Publicado: (2021)

Effect of HER2 expression status on the prognosis of patients with HR(+)/HER2(‑) advanced breast cancer undergoing advanced first‑line endocrine therapy
por: Wang, Kan, et al.
Publicado: (2023)

MicroRNA expression profiling of endocrine sensitive and resistant breast cancer cell lines
por: Khajah, Maitham A., et al.
Publicado: (2022)

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
por: Omarini, Claudia, et al.
Publicado: (2020)

Meeting Report: Measuring Endocrine-Sensitive Endpoints within the First Years of Life
por: Arbuckle, Tye E., et al.
Publicado: (2008)

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
por: Koeberle, Dieter, et al.
Publicado: (2007)

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
por: Koeberle, Dieter, et al.
Publicado: (2007)

Effects of Hormones and Endocrine Disorders on Hair Growth
por: Hasan, Rishi, et al.
Publicado: (2022)

First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Shimoi, Tatsunori, et al.
Publicado: (2020)

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
por: Hua, Xin, et al.
Publicado: (2022)

Deciphering Key Pharmacological Pathways of Qingdai Acting on Chronic Myeloid Leukemia Using a Network Pharmacology-Based Strategy
por: Li, Huayao, et al.
Publicado: (2018)

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
por: Zhang, Peng-Fei, et al.
Publicado: (2021)

SNP mutation‐related genes in breast cancer for monitoring and prognosis of patients: A study based on the TCGA database
por: Gao, Chundi, et al.
Publicado: (2019)

Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer
por: Gao, Chundi, et al.
Publicado: (2020)

7-lncRNA Assessment Model for Monitoring and Prognosis of Breast Cancer Patients: Based on Cox Regression and Co-expression Analysis
por: Li, Huayao, et al.
Publicado: (2019)

Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis
por: Gao, Chundi, et al.
Publicado: (2021)

Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study
por: Yuan, Yang, et al.
Publicado: (2021)

The role of hormonal factors and endocrine therapy in ovarian cancer
por: Serkies, Krystyna, et al.
Publicado: (2013)

Gender in Endocrine Diseases: Role of Sex Gonadal Hormones
por: Lauretta, R., et al.
Publicado: (2018)

Vitamin A, endocrine tissues and hormones: interplay and interactions
por: Brossaud, J, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1jfnpkee95d16i511o0ccdap4j